retatrutide phase 2 trial type 2 diabetes weight loss 2024 Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in and A1C Retatrutide TRIUMPH-4 Results: Are We

While published subgroup analyses focus primarily on diabetes status rather than age categories, the available data allows for some preliminary observations about younger participants

Analytical validation standards applicable to research-compound quality testing

In the head-to-head SURMOUNT trial, funded by drug manufacturer Eli Lilly, people who took tirzepatide lost more weight than those who took semaglutide (Ozempic)

Retatrutide is not yet FDA approved, unlike many GLP-1 agonists, retatrutide will most likely be a weekly injection, delivered subcutaneously into the arm, thigh or stomach area in a self-inject pen

As the ABC noted in its reporting on the Victorian cases, the injectable medication has not been approved by any worldwide drug regulator. It is still moving through clinical trials, where it is one of the most effective compounds the obesity field has ever produced